Citi keeps a Buy rating on West Pharmaceutical (WST) with a $300 price target while adding an “upside 90-day short-term view.” The firm views West as one of the stronger margin stories in the space, and sees potential room for upside to consensus earnings estimates this year “when the temporary headwinds are in the rearview.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical Services Hosts 2025 Shareholder Meeting
- West Pharma Faces Class Action Over Alleged Fraud
- West Pharmaceutical Services Earnings Call: Mixed Sentiments and Strategic Shifts
- West Pharmaceutical Services Reports Q1 2025 Earnings
- West Pharmaceutical Services: Strong Q1 Performance and Raised 2025 Guidance Justify Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue